What Facebook and Google billionaires could do for overlooked biotech brains

Americans are more likely to know the names of Tom Brady's kids than the names of the last couple of scientists to win Nobel prizes in medicine. That's because our fame-infatuated culture doesn't celebrate top scientists nearly as much as quarterbacks and movie stars and talentless pop singers. As Xconomy's biotech editor Luke Timmerman notes, the Breakthrough Prize in Life Sciences, announced last week, takes steps toward putting scientists in the spotlight and funding their labs with millions of dollars from the deep pockets of tech icons like Facebook's Mark Zuckerberg and Google's Sergey Brin, among others. Brin, a Google co-founder and billionaire, nailed it: "Curing a disease should be worth more than a touchdown." Timmerman's take

 

 

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.